Validate Early with CETSA®
Accelerate hit confirmation and lead optimization with CETSA® from Pelago Bioscience. This application note highlights how CETSA enhances small-molecule drug discovery by confirming target engagement directly in unmodified cellular systems—reducing costs and improving success rates. Discover case studies featuring collaborations with AstraZeneca on CRAF, PARP1, and BRAF inhibitors, showcasing CETSA’s ability to identify relevant hits, validate leads, and guide SAR analysis.
Download now to learn how CETSA can streamline your hit discovery process and support confident decision-making from screening to lead optimization.
References
- Jafari et al. Nature Protocols 2014
- Rowlands et al. SLAS Discovery 2023
- Shaw et al. SLAS Discovery 2018
